

GLENN HEGAR TEXAS COMPTROLLER OF PUBLIC ACCOUNTS

MEMORANDUM

January 26, 2022

TO: Internal Memo

FROM: Amanda Lopez, Director of Texas Opioid Abatement Fund Council

RE: FY 2022 and 2023 Revenue and Expenditures from Settlement

Agreements/Court Orders

This memorandum reflects funds received from the settlement agreements or court orders as of January 2023 totaling \$ 390,005,258.32 net attorney fees.

	Source	Amount	Description
			Opioid Abatement Account/ State share;
2022	McKinsey	4,540,343.02	Unappropriated
			Opioid Abatement Account/ State share;
2022	McKinsey	197,362.26	Unappropriated
			Opioid Abatement Account/ State share;
2022	J&J/Jansen	39,492,329.75	Unappropriated
			Opioid Abatement Account/ State share;
2022	Endo	8,373,408.75	Unappropriated
			Opioid Abatement Account/ State share;
2022	Teva	4,730,437.50	Unappropriated
	Global		
	Opioid		Opioid Abatement Account/ State share;
2023	Distributors	11,820,474.74	Unappropriated
	Total	69,154,356.02	

2022	Endo	38,575,907.50	Trust fund share
		, ,	
2022	Teva	22,075,375.00	Trust fund share
2023	J&J/Jansen	164,004,732.50	Trust fund share
	Global		
	Opioid		
2023	Distributors	25,325,280.96	Trust fund share
2022	Interest	1,934,444.38	Trust fund share interest
2023	Distribution	(5,000,000.00)	Texas Access to Justice Foundation Payment
	Total	246,915,740.34	

	Source	Amount	Description
2022	Endo	7,873,408.75	Subdivision share (Municipalities/counties)
2022	Teva	4,730,437.50	Subdivision share (Municipalities/counties)
2023	J&J/Jansen	30,166,610.48	Subdivision share (Municipalities/counties)
	Global		
	Opioid		
2023	Distributors	3,940,050.62	Subdivision share (Municipalities/counties)
			Subdivision share interest
2022	Interest	377,658.01	(Municipalities/counties)
	Total	47,088,165.36	

2021	McKinsey	25,728,610.44	Unappropriated General Revenue
2022	McKinsev	1,118,386.16	Unappropriated Conoral Poyonus
2022	Wickinsey	1,110,300.10	Unappropriated General Revenue
	Total	26,846,996.60	